Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT03520075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 7, 2018
Completion date
March 3, 2025
Enrollment
192 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult